SERINC2

Across TCGA pan-cancer cohorts, SERINC2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of SERINC2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SERINC2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SERINC2 is over-expressed in tumor, although a few such as READ and COAD show the opposite, repressed pattern.

HNSC, THCA, and LUAD are the cancer types where SERINC2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SERINC2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	All	+1.561	<.001	12	view →
THCA	Male	III,IV	+1.785	<.001	11	view →
LUAD	Female	III,IV	+2.562	<.001	9	view →
LUSC	All	III,IV	+2.335	<.001	9	view →
BLCA	All	III,IV	+2.884	.005	7	view →
UCEC	All	All	+3.606	<.001	6	view →
BRCA	All	III,IV	+1.650	<.001	6	view →
READ	Male	All	−1.643	<.001	6	view →
LIHC	Female	All	+1.085	<.001	6	view →
COAD	Female	II,III,IV	−0.829	<.001	6	view →
KICH	All	All	−1.011	<.001	5	view →
STAD	All	All	+1.913	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

SERINC2–HNSC

Open the HNSC breakdown →